E. Bajetta

513 total citations
22 papers, 384 citations indexed

About

E. Bajetta is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, E. Bajetta has authored 22 papers receiving a total of 384 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 7 papers in Epidemiology. Recurrent topics in E. Bajetta's work include Colorectal Cancer Treatments and Studies (8 papers), Cancer Treatment and Pharmacology (8 papers) and Neuroendocrine Tumor Research Advances (6 papers). E. Bajetta is often cited by papers focused on Colorectal Cancer Treatments and Studies (8 papers), Cancer Treatment and Pharmacology (8 papers) and Neuroendocrine Tumor Research Advances (6 papers). E. Bajetta collaborates with scholars based in Italy, United States and Germany. E. Bajetta's co-authors include Colin Germond, Christian Jacques, E. Lin, J. Randolph Hecht, Roberto Buzzoni, N. Cascinelli, Michele Del Vecchio, Jean‐Yves Douillard, Alberto Fusi and Malcolm J. Moore and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Annals of Oncology.

In The Last Decade

E. Bajetta

22 papers receiving 372 citations

Peers

Countries citing papers authored by E. Bajetta

Since Specialization

Citations

This map shows the geographic impact of E. Bajetta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Bajetta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Bajetta more than expected).

Fields of papers citing papers by E. Bajetta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Bajetta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Bajetta. The network helps show where E. Bajetta may publish in the future.

Co-authorship network of co-authors of E. Bajetta

This figure shows the co-authorship network connecting the top 25 collaborators of E. Bajetta. A scholar is included among the top collaborators of E. Bajetta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Bajetta. E. Bajetta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	3056 POSTER Effect of Palonosetron Plus 1-day Dexamethasone (DEX) on the Prevention of Delayed Nausea and Vomiting Due to Moderately Emetogenic Chemotherapy (MEC): a Pooled Analysis of Two Phase III Trials 2011 ·European Journal of Cancer ·Luigi Celio, E. Bonizzoni, E. Bajetta, Silvia Sebastiani, Tania Perrone, Matti Aapro	1
2	Phase II study of danusertib (D) in advanced/metastatic colorectal and pancreatic cancers (CRC, PC). 2010 ·Journal of Clinical Oncology ·B. Laffranchi, Maja J. De Jonge, E. Bajetta, Alain Hendlisz, Rosa Giuliani, C. Barone, Esther Endlicher, M.G. Jannuzzo, R. Spinelli, Armando Santoro	6
3	Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study 2009 ·Annals of Oncology ·Luigi Celio, Cora N. Sternberg, Roberto Labianca, Ignazia La Torre, Vito Amoroso, Carlo Barone, G. Pinotti, Stefano Cascinu, Francesco Di Costanzo, Gianluigi Cetto, E. Bajetta	16
4	Single-day regimen of palonosetron (PALO) and dexamethasone (DEX) for the prevention of emesis associated with moderately emetogenic chemotherapy (MEC): Subgroup analysis from a randomized phase III trial 2009 ·Journal of Clinical Oncology ·Luigi Celio, E. Bajetta, (unknown), E. Bichisao, S. Frustaci, Antonio Ardizzoia, E. Piazza, Alessandra Fabi, A. Capobianco, L. Isa	3
5	1323 mTOR expression in gastrointestinal (GI) tract poorly differentiated endocrine carcinoma (PDEC) 2009 ·European Journal of Cancer Supplements ·Laura Catena, A. Carbone, Massimo Milione, Marco Platania, Monika Ducceschi, (unknown), Lorenza Di Guardo, Roberto Buzzoni, Barbara Formisano, E. Bajetta	1
6	9011 NGR-hTNF, a vascular targeting agent (VTA), in previously treated patients with malignant pleural mesothelioma (MPM): a phase II study 2009 ·European Journal of Cancer Supplements ·Vanesa Gregorc, Giovanni Luca Ceresoli, Paolo Andrea Zucali, Filippo de Braud, E. Bajetta, Armando Santoro, Maria Grazia Viganò, F. Caligaris Cappio, A. Lambiase, Claudio Bordignon	2
7	Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), in previously treated patients with malignant pleural mesothelioma (MPM) 2009 ·Journal of Clinical Oncology ·Vanesa Gregorc, Giovanni Luca Ceresoli, Paolo Andrea Zucali, Filippo de Braud, E. Bajetta, Armando Santoro, Maria Grazia Viganò, Federico Caligaris‐Cappio, A. Lambiase, Claudio Bordignon	2
8	Efficacy and safety of first-line bevacizumab (BEV) plus interferon-α2a (IFN) in patients (pts) ≥65 years with metastatic renal cell carcinoma (mRCC) 2008 ·Journal of Clinical Oncology ·E. Bajetta, Alain Ravaud, Sergio Bracarda, Sylvie Négrier, Cezary Szczylik, (unknown), N. Moore, Pavel Pisa, Bernard Escudier	18
9	NGR-hTNF, a novel vascular targeting agent (VTA), as second-line therapy in malignant pleural mesothelioma (MPM): Preliminary results of multicenter phase II study 2008 ·Journal of Clinical Oncology ·Vanesa Gregorc, Paolo Andrea Zucali, Giovanni Luca Ceresoli, Cristina Noberasco, E. Bajetta, Armando Santoro, Maria Grazia Viganò, Federico Caligaris‐Cappio, A. Lambiase, Claudio Bordignon	3
10	Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): Efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis 2008 ·Journal of Clinical Oncology ·B. Escudier, Alain Ravaud, Sylvie Négrier, Cezary Szczylik, (unknown), Sergio Bracarda, Pavel Pisa, Jacques Gaudreault, E. Bajetta	35
11	Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-α2b in metastatic melanoma 2006 ·Annals of Oncology ·E. Bajetta, Michele Del Vecchio, (unknown), Alberto Fusi, Antonio Daponte, M.R. Sertoli, Paola Queirolo, (unknown), Maria Grazia Bernengo, Sewa S. Legha, Barbara Formisano, N. Cascinelli	83
12	Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients (pts) with previously treated metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM 2) 2006 ·Journal of Clinical Oncology ·(unknown), E. Bajetta, E. Lin, Eric Van Cutsem, J. Randolph Hecht, Jean‐Yves Douillard, Malcolm J. Moore, Colin Germond, Laurent Dembélé, Christian Jacques	69
13	Level of circulating endothelial cells as new biomarker in patients with multiple myeloma, treated with bortezomib-pegylated liposomal doxorubicin-dexamethasone combination 2006 ·Journal of Clinical Oncology ·Arpine Gevorgyan, Vincenzo Pitini, (unknown), Giuseppe Altavilla, (unknown), (unknown), Giuseppe Procopio, Elena Verzoni, Marco Platania, E. Bajetta	1
14	Phase II study of pemetrexed disodium (Alimta®) administered with oral folic acid in patients with advanced gastric cancer 2003 ·Annals of Oncology ·E. Bajetta, Luigi Celio, Roberto Buzzoni, L. Ferrari, Alfonso Marchianò, Antonia Martinetti, R. Longarini, Carlos Becerra, Carl F. Ilardi, (unknown)	49
15	117 Oxaliplatin plus capecitabine in advanced neuroendocrine tumours (NETs): Is the new WHO classification applicable to daily practice? 2003 ·European Journal of Cancer Supplements ·Laura Catena, E. Bajetta, Giuseppe Procopio, L. Ferrari, S. Della Torre, Elena Verzoni, E. Bichisao, Roberto Buzzoni, S. Iacobelli, Alfredo Falcone	2
16	Palliative Therapie bei metastasiertem Mammakarzinom mit Tamoxifen und hochdosiertem Octreotid (Somatostatin-Analog) - Ergebnisse einer multizentrischen Phase-III-Studie 2001 ·Zentralblatt für Gynäkologie ·H. Sommer, (unknown), E. Bajetta, Ulrike Haus, W Janni, (unknown)	3
17	Activity and safety of capecitabine and irinotecan (CPT-11) in association as first line chemotherapy in advanced colorectal cancer (ACRC) 2001 ·European Journal of Cancer ·E. Bajetta, Diego Cortinovis, Antonio Cassata, Salvatore Siena, G. Cartei, G. Pinotti, (unknown), A. Lambiase	6
18	[Adjuvant chemotherapy following liver metastasis resection in neoplasms of the colorectum]. 1997 ·PubMed ·E. Bajetta, Michele Del Vecchio, Roberto Buzzoni	1
19	Home Treatment with Interleukin 2 and β-Interferon in Patients with Colorectal Cancer and Hepatocellular Carcinoma 1994 ·Oncology ·Filippo de Braud, Marco Colleoni, (unknown), E. Bajetta	2
20	A clinical study of the pineal gland activity in oncologic patients 1986 ·Cancer ·Paolo Lissoni, Simonetta Viviani, E. Bajetta, Roberto Buzzoni, Antonella Barreca, R Mauri, (unknown), Francesco Carlo Morabito, D. Esposti, G. Esposti, F. Fraschini	36

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact